Healthcare Finance News October 18, 2023
HHS wants to ensure affordable access for beneficiaries in public programs such as Medicare and Medicaid, and for the uninsured.
The Department of Health and Human Services has reached an agreement with Pfizer to extend patient access to Paxlovid, which is authorized for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients.
The drug is targeted at patients 12 years old and older who are at high risk for progression to severe COVID-19, including hospitalization or death.
The agreement also “maximizes taxpayer investment,” according to HHS, and begins Paxlovid’s transition to the commercial market in November 2023.
A partnership between HHS and Pfizer over the last three years enabled the development, manufacture, and distribution of COVID-19 vaccines and therapeutics...
Today's Sponsors
Today's Sponsor